Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 1 11Phase 1/2 8Phase 3 4Phase NA 1

Status

Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Kidney Neoplasms 1Genital Diseases, Male 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Pluvicto × Clear all
NCT06959433 2026-02-27

Lu-177 PSMA Treatment in Cell Renal Carcinoma

Ankara University

Phase 3 Not yet recruiting
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07200830 2025-10-01

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
1,524 enrolled
Genitourinary

Prostatic Neoplasms

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting
3,360 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡